Biotech

All Articles

Amgen files very first phase 3 win for $400M eczema drug

.Amgen has actually discussed (PDF) the very first period 3 records on its $400 million dermatitis d...

Biogen, UCB report stage 3 lupus gain after failing earlier trial

.Biogen and also UCB's bet one's bottom dollar improving into phase 3 astride a failed study aims to...

Aptadir hopes brand new RNA inhibitors can easily turn around complicated cancers cells

.Italian biotech Aptadir Therapeutics has introduced along with the commitment that its pipe of prec...

Wave surfs DMD effectiveness to regulators' doors, sending out stockpile

.Wave Life Sciences has fulfilled its own goal in a Duchenne muscle dystrophy (DMD) research study, ...

Sanofi plucks new CSO from in-stealth biotech

.After a few years in biotech, Mike Quigley, Ph.D., is actually returning to the pharma layer, occup...

Achilles drops cell treatment program, braces for cutbacks after skipping 'office feasibility' objectives

.Achilles Therapies has shreded its own strategy. The British biotech is actually quiting working on...

Aligos proclaims phase 2 MASH succeed, lowering liver body fat as much as 46%

.Aligos Therapeutics is actually declaring a midstage win in metabolic-dysfunction associated steato...

Basilea ratings $268M BARDA backing for antifungals, anti-biotics

.Basilea Pharmaceutica's work cultivating brand new antifungals has actually obtained a notable impr...

Capricor markets Europe legal rights to late-stage DMD therapy for $35M

.Having already gathered up the united state rights to Capricor Rehabs' late-stage Duchenne muscular...

FDA junks adcomm for Applied's uncommon health condition medicine

.After pushing back the selection meeting for Applied Rehabs' metabolic problem medicine govorestat,...